| Title |
MEK inhibitors for the treatment of NRAS mutant melanoma
|
|---|---|
| Published in |
Drug Design, Development and Therapy, August 2018
|
| DOI | 10.2147/dddt.s131721 |
| Pubmed ID | |
| Authors |
Saro Sarkisian, Diwakar Davar |
| Abstract |
Melanoma is increasing rapidly in incidence and prevalence, especially in younger females and older males. Treatment options have expanded beyond high-dose interleukin 2 and adoptive T-cell therapy to include inhibitors of immune checkpoints programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and small molecular inhibitors of pathways activated in melanoma, in particular the mitogen-activated protein kinase (MAPK) pathway. PD-1/CTLA-4 inhibitors and inhibitors of MAPK such as BRAF/MEK inhibitors have significantly improved survival in both the metastatic and, more recently, adjuvant settings. In this review, we discuss the preclinical data, clinical development, and potential use of novel MEK inhibitor binemetinib, particularly in the setting of NRAS mutant melanoma. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 67% |
| Australia | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 72 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 11 | 15% |
| Researcher | 9 | 13% |
| Student > Bachelor | 8 | 11% |
| Student > Doctoral Student | 6 | 8% |
| Student > Ph. D. Student | 6 | 8% |
| Other | 7 | 10% |
| Unknown | 25 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 22% |
| Biochemistry, Genetics and Molecular Biology | 14 | 19% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Chemistry | 3 | 4% |
| Agricultural and Biological Sciences | 2 | 3% |
| Other | 5 | 7% |
| Unknown | 29 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 December 2023.
All research outputs
#2,214,053
of 25,477,125 outputs
Outputs from Drug Design, Development and Therapy
#111
of 2,272 outputs
Outputs of similar age
#44,089
of 342,141 outputs
Outputs of similar age from Drug Design, Development and Therapy
#4
of 69 outputs
Altmetric has tracked 25,477,125 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,272 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,141 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.